Kumamoto Medical Center

Prior vedolizumab exposure and fibroblast-derived MMP13 are associated with ustekinumab nonresponse in ulcerative colitis

Abstract Background As therapeutic options for ulcerative colitis increase, optimizing the sequencing of advanced therapies has become an important challenge. We examined whether baseline clinical characteristics influence the effectiveness of ustekinumab and investigated molecul...

Relationship between initial dose, dose intensity, and survival in unresectable pancreatic cancer treated with nanoliposomal irinotecan, fluorouracil, and folinic acid

Abstract While nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard second-line regimen for unresectable pancreatic cancer (uPC) after gemcitabine-based therapy, the effects of initial dosing and relative dose intensity (RDI) in routine practice are unc...